Drug Expiration Date Rationale Requested By Waxman
This article was originally published in The Tan Sheet
Data on FDA's expiration date policies and safety/ effectiveness standards for OTC and Rx drugs are requested by Rep. Henry Waxman (D-Calif.) in a May 19 letter to FDA.
You may also be interested in...
Additional research is needed to determine whether longer drug product shelf lives would lower drug costs, the American Medical Association Council on Scientific Affairs says in a report prepared for the AMA House of Delegates meeting in Chicago June 17-21.
Congressional leaders may be looking to the 107th Congress to initiate hearings on FDA's actions in implementing the Pearson v. Shalala decision.
Preservation of the three-year exclusivity awarded for clinical studies supporting Rx-to-OTC switches under the existing Waxman/Hatch Act is the Consumer Healthcare Products Association's top priority as patent reform discussions take shape on Capitol Hill.